BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...against NCR1 is a bispecific antibody from Innate Pharma...
BioCentury | Dec 12, 2020
Regulation

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

...including a recommendation for Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) to treat psoriatic arthritis and ankylosing spondylitis.Separately, Innate Pharma S.A....
...Seagen Inc. [MERGED] AstraZeneca plc [MERGED] Celltrion Healthcare Co. Ltd. [MERGED] AbbVie Gilead Sciences Inc. Daiichi Sankyo Co. Ltd. Seagen Inc. AstraZeneca plc Innate Pharma S.A. Dynavax...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...shp-141, SHAPE) lacutamab (IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen (MRG-106) hypericin (HBP-347, SGX301) Rhizen Pharmaceuticals S.A. Soligenix Inc. miRagen Therapeutics Inc. CerRx Inc. Innate Pharma S.A. BioCryst...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...will become COO. Mulroy was CFO of La Jolla Pharmaceutical Co. (NASDAQ:LJPC). French cancer company Innate Pharma S.A....
...SVP, head of clinical development at LogicBio Therapeutics Inc. (NASDAQ:LOGC). Robin Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...using plasmacytoid dendritic cells, appointed Mondher Mahjoubi as chairman. He is chairman and CEO of Innate Pharma S.A....
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...Roche (SIX:ROG; OTCQX:RHHBY) have each expressed interest in the target. According to BioCentury’s BCIQ database, Innate Pharma...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...BI 754091 ( No. 3063 ). New checkpoint data aren’t limited to T cell targets. Innate Pharma S.A....
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...different means, different groups have identified SIGLECs as potential players in cancer immunotherapy," said Läubli. Innate Pharma S.A....
...clinical trial testing CD24Fc in metabolic disorders, and is exploring inhibiting the pathway in cancer. Innate Pharma...
...Sialic acid binding Ig like lectin 15 Karen Tkach Tuzman, Associate Editor Palleon Pharmaceuticals Inc. Scripps Research NextCure Inc. Allakos Inc. Innate Pharma S.A. Alector...
BioCentury | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

...vaccine. EMA reviewing Innate’s hairy cell leukemia candidate EMA accepted for review an MAA from Innate Pharma S.A....
...Spleen tyrosine kinase BioCentury Staff Elizabeth S. Eaton and Hongjiang Li, Staff Writers Xiamen Innovax Biotech Co. Ltd. Innate Pharma S.A. Pulmatrix...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...other C5AR1-targeting program, according to BioCentury's BCIQ database. One mAb against the target, IPH5401 from Innate Pharma S.A....
Items per page:
1 - 10 of 201
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...against NCR1 is a bispecific antibody from Innate Pharma...
BioCentury | Dec 12, 2020
Regulation

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

...including a recommendation for Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) to treat psoriatic arthritis and ankylosing spondylitis.Separately, Innate Pharma S.A....
...Seagen Inc. [MERGED] AstraZeneca plc [MERGED] Celltrion Healthcare Co. Ltd. [MERGED] AbbVie Gilead Sciences Inc. Daiichi Sankyo Co. Ltd. Seagen Inc. AstraZeneca plc Innate Pharma S.A. Dynavax...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...shp-141, SHAPE) lacutamab (IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen (MRG-106) hypericin (HBP-347, SGX301) Rhizen Pharmaceuticals S.A. Soligenix Inc. miRagen Therapeutics Inc. CerRx Inc. Innate Pharma S.A. BioCryst...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...will become COO. Mulroy was CFO of La Jolla Pharmaceutical Co. (NASDAQ:LJPC). French cancer company Innate Pharma S.A....
...SVP, head of clinical development at LogicBio Therapeutics Inc. (NASDAQ:LOGC). Robin Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...using plasmacytoid dendritic cells, appointed Mondher Mahjoubi as chairman. He is chairman and CEO of Innate Pharma S.A....
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...Roche (SIX:ROG; OTCQX:RHHBY) have each expressed interest in the target. According to BioCentury’s BCIQ database, Innate Pharma...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...BI 754091 ( No. 3063 ). New checkpoint data aren’t limited to T cell targets. Innate Pharma S.A....
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...different means, different groups have identified SIGLECs as potential players in cancer immunotherapy," said Läubli. Innate Pharma S.A....
...clinical trial testing CD24Fc in metabolic disorders, and is exploring inhibiting the pathway in cancer. Innate Pharma...
...Sialic acid binding Ig like lectin 15 Karen Tkach Tuzman, Associate Editor Palleon Pharmaceuticals Inc. Scripps Research NextCure Inc. Allakos Inc. Innate Pharma S.A. Alector...
BioCentury | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

...vaccine. EMA reviewing Innate’s hairy cell leukemia candidate EMA accepted for review an MAA from Innate Pharma S.A....
...Spleen tyrosine kinase BioCentury Staff Elizabeth S. Eaton and Hongjiang Li, Staff Writers Xiamen Innovax Biotech Co. Ltd. Innate Pharma S.A. Pulmatrix...
BioCentury | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

...other C5AR1-targeting program, according to BioCentury's BCIQ database. One mAb against the target, IPH5401 from Innate Pharma S.A....
Items per page:
1 - 10 of 201